NEW YORK, Dec. 02, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Adeptus Health securities (NYSE:ADPT): (1) from April 23, 2015 through November 16, 2015, both dates inclusive; and/or (2) pursuant and/or traceable to Adeptus Health’s secondary public offering on or about July 31, 2015 of the important December 27, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Adeptus Health investors under the federal securities laws.
To join the Adeptus Health class action, go to http://rosenlegal.com/cases-789.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Adeptus Health was engaging in predatory billing practices, which exposed Adeptus Health to numerous risks and possible penalties, including civil and/or criminal sanctions, and exclusion from federal and/or state healthcare programs; (2) Adeptus Health’s financial statements had not been prepared in conformity with generally accepted accounting principles; and (3) contrary to representations about Adeptus Health’s practice of referring lower acuity patients to urgent care facilities, it routinely treated and excessively billed these patients. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 27, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-789.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 



